首页|载药微球化疗栓塞术治疗中晚期肝癌患者疗效及对血清GGT、钙磷代谢的影响

载药微球化疗栓塞术治疗中晚期肝癌患者疗效及对血清GGT、钙磷代谢的影响

扫码查看
目的 探讨中晚期肝癌患者采取载药微球化疗栓塞术的疗效.方法 选取2018年5月至2023年1月阜阳市人民医院收治的65例中晚期肝癌患者,按不同手术方法分为2组,对照组(肝动脉化疗栓塞术)31例,观察组(载药微球化疗栓塞术)34例,比较两组疗效.结果 观察组GGT(28.26±2.62)U/L低于对照组(53.99±3.71)U/L;CA19-9(6.84 ±0.26)U/mL 低于对照组(12.58±0.48)U/mL;AFP(310.87±5.52)ng/mL 低于对照组(459.26±6.18)ng/mL(t=32.522、60.674、102.256,P<0.05).术后 1 个月,观察组血 Ga(2.12±0.14)mmol/L、iPTH(179.56±19.52)pg/mL、钙磷乘积(45.86±3.62)mg2/dL 均低于对照组的(2.20±0.15)mmol/L、(206.84±22.17)pg/mL、(51.47±4.26)mg2/dL,血 P(1.56±0.13)mmol/L 高于对照组(1.83±0.14)mmol/L,钙磷乘积(45.86±3.62)mg2/dL 低于对照组(51.47±4.26)mg2/dL(t=2.224、5.275、5.737、8.062,均 P<0.05).术后 1 个月,观察组 ALT(44.26±3.52)U/L 低于对照组(53.97± 4.17)U/L,AST(36.85±5.14)U/L 低于对照组(48.10±6.71)U/L,TBil(16.56±2.62)μmol/L 低于对照组(21.45± 3.05)μmol/L(t=10.174、7.627、6.951,P<0.05).两组不良反应发生率对比(x2=0.300,P=0.584).术后 3 个月,两组生存率为97.06%比90.32%,差异无统计学意义(x2=0.375,P=0.540);术后6个月,两组生存率94.12%比70.97%,差异有统计学意义(x2=6.181,P=0.013).结论 载药微球化疗栓塞术治疗中晚期肝癌患者疗效确切,随访6个月患者生存率较高,值得推广.
Effect of chemoembolization with drug-loaded microspheres on therapeutic effect and serum GGT,calcium and phosphorus metabolism in patients with advanced liver cancer
Objective To investigate the efficacy of chemoembolization with drug-loaded microspheres in patients diagnosed with advanced liver cancer.Methods A total of 65 patients with advanced liver cancer treated between May 2018 and January 2023,were divided into 2 groups based on the surgical method used:control group(31 cases:conventional surgery)and observation group(34 cases:drug-loaded microsphere chemoembolization).The efficacy of these two treatment approaches was compared.Results The level of glutamyltransferase(GGT)in the observation group(28.26± 2.62 U/L)was significantly lower compared to the control group(53.99±3.71 U/L).Similarly,the levels of CA19-9(6.84±0.26 U/mL)and AFP(310.87±5.52 ng/ml)were also lower in the observation group than in the control group(459.26±6.18 ng/ml)(t=32.522,P<0.05;t value=60.674,P<0.05;t value=102.256,P<0.05).1 month pose-surgery,the blood concentrations of Ca(2.12±0.14 mmol/L),iPTH(179.56±19.52 pg/mL)and Ca × P product(45.86±3.62 mg2/dL)in the observation group showed a significantly decrease compared to the control group(2.20± 0.15 mmol/L,206.84±22.17 pg/mL,51.4 7±4.26 mg2/dL).Additionally,the level of blood phosphorus(1.56±0.13 mmol/L)was higher in the observation group than in the control group(1.83±0.14 mmol/L),while the product of calcium and phosphorus(45.86±3.62 mg2/dL)was lower in the observation group compared to the control group(51.47 ±4.26 mg2/dL)(t value=2.224,P<0.05;t value=5.275,P<0.05;t value=5.737,P<0.05;t value=8.062,P<0.05).Moreover,one month after the operation,the levels of ALT(44.26±3.52 U/L),AST(36.85±5.14 U/L),and Tbil(16.56±2.62)μmol/L were lower than those in the control group(53.97±4.17 U/L,48.10±6.71 U/L,21.45± 3.05 μmol/L,respectively).(t=10.174,P<0.05;t value=7.627,P<0.05;t value=6.951,P<0.05).The incidence of adverse reactions between the two groups was compared(x2=0.300,P=0.584).Survival rates at 3 month(x2=0.375,P=0.540)and 6 months(x2=6.181,P=0.013)after surgery were also compared.Conclusion Chemoembolization with drug-loaded microspheres has demonstrated effectiveness in the treatment advanced liver cancer patients,with a high survival rate observed at 6 months post-surgery.This treatment approach warrants further investigation and potential application in clinical practice.

Advanced liver cancerChemoembolization with drug-loaded microspheresCalcium and phosphorus metabolism

苗晓飞、王洪剑

展开 >

236000 安徽 阜阳市人民医院影像中心

236000 安徽 阜阳市人民医院介入放射科

中晚期肝癌 载药微球化疗栓塞术 钙磷代谢

2020年度安徽省自然科学基金

2008085MB32

2024

肝脏
上海市医学会

肝脏

CSTPCD
影响因子:0.71
ISSN:1008-1704
年,卷(期):2024.29(3)
  • 20